Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct;134(4):818-23.
doi: 10.1016/j.jaci.2014.08.005.

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

Eric L Simpson  1 , Joanne R Chalmers  2 , Jon M Hanifin  3 , Kim S Thomas  2 , Michael J Cork  4 , W H Irwin McLean  5 , Sara J Brown  5 , Zunqiu Chen  6 , Yiyi Chen  7 , Hywel C Williams  2
Affiliations
Randomized Controlled Trial

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

Eric L Simpson et al. J Allergy Clin Immunol. 2014 Oct.

Abstract

Background: Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence. Because of the significant socioeconomic effect of atopic dermatitis and its effect on the quality of life of children and families, there have been decades of research focused on disease prevention, with limited success. Recent advances in cutaneous biology suggest skin barrier defects might be key initiators of atopic dermatitis and possibly allergic sensitization.

Objective: Our objective was to test whether skin barrier enhancement from birth represents a feasible strategy for reducing the incidence of atopic dermatitis in high-risk neonates.

Methods: We performed a randomized controlled trial in the United States and United Kingdom of 124 neonates at high risk for atopic dermatitis. Parents in the intervention arm were instructed to apply full-body emollient therapy at least once per day starting within 3 weeks of birth. Parents in the control arm were asked to use no emollients. The primary feasibility outcome was the percentage of families willing to be randomized. The primary clinical outcome was the cumulative incidence of atopic dermatitis at 6 months, as assessed by a trained investigator.

Results: Forty-two percent of eligible families agreed to be randomized into the trial. All participating families in the intervention arm found the intervention acceptable. A statistically significant protective effect was found with the use of daily emollient on the cumulative incidence of atopic dermatitis with a relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-0.9; P = .017). There were no emollient-related adverse events and no differences in adverse events between groups.

Conclusion: The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe, and effective approach for atopic dermatitis prevention. If confirmed in larger trials, emollient therapy from birth would be a simple and low-cost intervention that could reduce the global burden of allergic diseases.

Keywords: Atopic dermatitis; eczema; emollients; prevention; skin barrier.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Skin barrier protection might prevent atopic dermatitis development. FLG, Filaggrin.
Fig 2
Fig 2
CONSORT flow diagram.
See this image and copyright information in PMC

Comment in

References

    1. Odhiambo J.A., Williams H.C., Clayton T.O., Robertson C.F., Asher M.I. ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124:1251–1258.e23. - PubMed
    1. Williams H., Stewart A., von Mutius E., Cookson W., Anderson H.R. International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947–954.e15. - PubMed
    1. Yaghmaie P., Koudelka C.W., Simpson E.L. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428–433. - PMC - PubMed
    1. Spergel J.M. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105:99–109. 117. - PubMed
    1. Foisy M., Boyle R.J., Chalmers J.R., Simpson E.L., Williams H.C. Overview of reviews the prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews. Evid Based Child Health. 2011;6:1322–1339. - PMC - PubMed

Publication types